1. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma
- Author
-
Tadashi Takeda, Tohru Adachi, Koji Saito, Takafumi Saito, Junitsu Ito, Etsuko Hattori, Hisayoshi Watanabe, Kazuo Okumoto, Sumio Kawata, Kazuhiko Sugahara, and Hitoshi Togashi
- Subjects
medicine.medical_specialty ,Cirrhosis ,Hepatology ,business.industry ,medicine.medical_treatment ,Cancer ,medicine.disease ,Gastroenterology ,Natural killer cell ,Interleukin 10 ,Infectious Diseases ,medicine.anatomical_structure ,Cytokine ,Immune system ,Hepatocellular carcinoma ,Internal medicine ,Immunology ,medicine ,Carcinoma ,business - Abstract
OBJECTIVES: Interleukin-10 (IL-10) has been implicated in immune deficiency in patients with cancer. The relationship of this cytokine as measured in serum to anti-tumor immunity and prognosis was investigated in unresectable hepatocellular carcinoma. METHODS: This study consisted of 74 consecutive patients with unresectable hepatocellular carcinoma (median age, 65 years). Forty-four healthy age-matched subjects and 32 patients with cirrhosis but no carcinoma served as controls. Patients with hepatocellular carcinoma were divided into those with serum IL-10 concentrations above (high group, n=39) or below (low group, n=35) 10pg/ml. RESULTS: Age, gender, Child-Pugh grade, and tumor stage distributions were similar in high and low groups. The patients of high group showed lower in lymphokine-activated killer (LAK) and natural killer (NK) activities than those of low group (P
- Published
- 2003
- Full Text
- View/download PDF